Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of
October 25 2010 - 5:19AM
PR Newswire (US)
GENEVA, October 25, 2010 /PRNewswire/ -- Merck Serono, a
division of Merck KGaA, Darmstadt, Germany, announced today that the two-year
Phase III REFLEX 1 study met its primary endpoint by demonstrating
that Rebif(R) (interferon beta-1a) significantly delayed conversion
to multiple sclerosis (MS) diagnosed according to the McDonald
criteria 2 in patients with a first clinical event suggestive of
the disease.
The international REFLEX study with 517 patients was conducted
with the serum-free formulation of Rebif(R) 3, which was first
introduced in 2007 and is now available in all European Union
countries, Australia, Canada and Switzerland, as well as a number of countries
in Asia, Latin America, Africa and the Middle East. The serum-free formulation of
Rebif(R) is currently not available in the United States.
The risk of conversion to MS (McDonald criteria) over two years
was reduced by 51% (p
Serono (NYSE:SRA)
Historical Stock Chart
From May 2024 to Jun 2024
Serono (NYSE:SRA)
Historical Stock Chart
From Jun 2023 to Jun 2024
